Immunovant, Inc. vs Johnson & Johnson — Stock Comparison
Immunovant, Inc. (IMVT) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson clearly outscores Immunovant, Inc. on Q·Score (7 vs 5 out of 10), led by Quality (9.3 vs 1.6) and Valuation (6.5 vs 6). Immunovant, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for IMVT (+33.4%) than for JNJ (+4.0%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
75% of 16 covering analysts have a positive rating.
⚠ low return on equity (-80%).
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
IMVT vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7/10 versus Immunovant, Inc. (IMVT) at 5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: IMVT or JNJ?
Immunovant, Inc. (IMVT) scores higher on Growth (5.1/10 vs 5/10). Immunovant, Inc. reports revenue growth while Johnson & Johnson reports (6.6% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is IMVT or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (6.5/10 vs 6/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about IMVT vs JNJ?
There are 16 analysts covering IMVT with a consensus price target of $48.88, and 22 analysts covering JNJ with a consensus target of $277.91. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: IMVT or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 1.6/10). Net profit margin: IMVT at 0.0%, JNJ at 21.5%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: IMVT or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 6.2/10). Market beta: IMVT at 0.81, JNJ at 0.23. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of IMVT and JNJ?
Immunovant, Inc. (IMVT) has a market capitalisation of $7.6B, while Johnson & Johnson (JNJ) has a market cap of $643.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do IMVT or JNJ pay dividends?
IMVT does not currently pay a dividend, while JNJ pays a dividend yield of 2.01%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →